Equities research analysts expect Regeneron Pharmaceuticals Inc (NASDAQ:REGN) to post $5.32 earnings per share for the current quarter, Zacks reports. Six analysts have made estimates for Regeneron Pharmaceuticals’ earnings, with estimates ranging from $4.55 to $5.73. Regeneron Pharmaceuticals posted earnings per share of $5.45 in the same quarter last year, which would indicate a negative year over year growth rate of 2.4%. The business is scheduled to issue its next quarterly earnings report on Thursday, August 1st.

On average, analysts expect that Regeneron Pharmaceuticals will report full year earnings of $21.78 per share for the current year, with EPS estimates ranging from $18.82 to $23.30. For the next financial year, analysts forecast that the company will post earnings of $24.98 per share, with EPS estimates ranging from $20.49 to $28.75. Zacks’ EPS calculations are a mean average based on a survey of analysts that that provide coverage for Regeneron Pharmaceuticals.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Tuesday, May 7th. The biopharmaceutical company reported $4.45 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $5.24 by ($0.79). The company had revenue of $1.71 billion for the quarter, compared to the consensus estimate of $1.76 billion. Regeneron Pharmaceuticals had a net margin of 35.13% and a return on equity of 26.95%. Regeneron Pharmaceuticals’s quarterly revenue was up 13.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $4.67 EPS.

Several research firms recently weighed in on REGN. Citigroup reduced their price target on shares of Regeneron Pharmaceuticals from $396.00 to $340.00 and set a “neutral” rating for the company in a research report on Thursday, May 23rd. ValuEngine upgraded shares of Regeneron Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, May 23rd. Credit Suisse Group began coverage on shares of Regeneron Pharmaceuticals in a research report on Monday, May 20th. They set a “neutral” rating and a $336.00 price target for the company. Cantor Fitzgerald reduced their price target on shares of Regeneron Pharmaceuticals from $441.00 to $405.00 and set a “neutral” rating for the company in a research report on Monday, May 13th. Finally, BMO Capital Markets reduced their price target on shares of Regeneron Pharmaceuticals from $412.00 to $375.00 and set a “market perform” rating for the company in a research report on Wednesday, May 8th. Two equities research analysts have rated the stock with a sell rating, fourteen have issued a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of $397.44.

REGN opened at $301.72 on Monday. The stock has a market cap of $33.65 billion, a P/E ratio of 15.24, a P/E/G ratio of 1.45 and a beta of 1.08. The company has a debt-to-equity ratio of 0.08, a current ratio of 4.58 and a quick ratio of 3.78. Regeneron Pharmaceuticals has a fifty-two week low of $291.69 and a fifty-two week high of $442.00.

In other news, Director Joseph L. Goldstein sold 1,000 shares of the stock in a transaction dated Wednesday, May 15th. The shares were sold at an average price of $305.93, for a total value of $305,930.00. Following the sale, the director now directly owns 11,323 shares of the company’s stock, valued at $3,464,045.39. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, major shareholder Sanofi sold 131,115 shares of the firm’s stock in a transaction that occurred on Friday, March 8th. The shares were sold at an average price of $412.17, for a total transaction of $54,041,669.55. The disclosure for this sale can be found here. Over the last three months, insiders sold 141,968 shares of company stock worth $57,360,056. Insiders own 11.84% of the company’s stock.

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Joel Isaacson & Co. LLC grew its holdings in shares of Regeneron Pharmaceuticals by 0.8% in the first quarter. Joel Isaacson & Co. LLC now owns 3,042 shares of the biopharmaceutical company’s stock worth $1,249,000 after purchasing an additional 25 shares during the last quarter. Cornerstone Advisors Inc. lifted its stake in Regeneron Pharmaceuticals by 3.7% in the first quarter. Cornerstone Advisors Inc. now owns 842 shares of the biopharmaceutical company’s stock worth $346,000 after acquiring an additional 30 shares during the period. Comprehensive Portfolio Management LLC lifted its stake in Regeneron Pharmaceuticals by 4.1% in the first quarter. Comprehensive Portfolio Management LLC now owns 833 shares of the biopharmaceutical company’s stock worth $342,000 after acquiring an additional 33 shares during the period. Kaizen Advisory LLC lifted its stake in Regeneron Pharmaceuticals by 21.2% in the fourth quarter. Kaizen Advisory LLC now owns 200 shares of the biopharmaceutical company’s stock worth $75,000 after acquiring an additional 35 shares during the period. Finally, OppenheimerFunds Inc. lifted its position in Regeneron Pharmaceuticals by 2.6% during the first quarter. OppenheimerFunds Inc. now owns 1,465 shares of the biopharmaceutical company’s stock valued at $602,000 after buying an additional 37 shares during the period. 66.97% of the stock is currently owned by institutional investors and hedge funds.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

Further Reading: Return On Assets

Get a free copy of the Zacks research report on Regeneron Pharmaceuticals (REGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.